Hook & thesis
Mirion Technologies (MIR) is a niche, mission-critical franchise in radiation safety and detection that sits at the intersection of two durable end markets: nuclear energy and medical imaging. After a sharp run to a 52-week high near $30 in late 2025, the stock retraced to its summer low of $14.11 on 07/29/2026; today it trades around $16.33. That swing has left a setup where near-term sentiment is cautious, but fundamentals point to continued revenue and order growth.
Our thesis: buy a controlled-sized long in MIR around $16.35 with a clear stop and defined targets. The company shows strong revenue momentum (recent quarterly prints and commentary point to mid-to-high double-digit growth rates and a 42% order surge reported in 2026 commentary), a meaningful free cash flow stream ($133.7 million last reported) and a large cash balance (about $1.49 billion) that dampens downside. Against this backdrop, the math supports a swing trade that can work if execution and the macro environment remain stable.
What the company does and why the market should care
Mirion provides radiation detection, safety, measurement and analysis systems across nuclear power, defense, laboratories and medical markets. These are not commodity products - they require technical certification, regulatory approvals and long sales cycles tied to projects and capital budgets. Investors should care because:
- End markets have structural tailwinds: nuclear power investments and tighter medical radiation safety rules supporting steady demand for detection and monitoring equipment.
- Order book and revenue momentum: public disclosures and coverage note revenue growth as high as 27% year-over-year in recent periods and a 42% jump in orders in early 2026, indicating backlog-driven visibility.
- Capital-light cash generation: Mirion reported free cash flow of $133.7 million and holds a substantial cash stockpile of about $1.49 billion, giving management flexibility on buybacks, bolt-on M&A and working capital.
Fundamentals & recent performance
Key published figures to anchor the view:
| Metric | Value |
|---|---|
| Current price | $16.33 |
| Market cap | $4.07 billion |
| Enterprise value | $4.79 billion |
| Free cash flow (most recent) | $133.7 million |
| Cash | $1.49 billion |
| Debt to equity | 0.66 |
| Price / Sales | ~3.9x |
| EV / EBITDA | ~23.4x |
| 52-week range | $14.11 - $30.28 |
Operationally, Mirion showed a strong revenue print in Q2 2025 of $222.9 million with adjusted EPS of $0.11 and raised full-year guidance at that time. Subsequent commentary through 2026 highlighted 27.5% revenue growth and a 42% orders expansion, signaling that topline momentum is not a one-off.
Valuation framing
On headline multiples Mirion is not cheap: a P/E north of 160 and an EV/EBITDA around 23.4x imply investors are paying for growth and execution. However, the balance sheet tells a different part of the story: with roughly $1.49 billion in cash vs a market cap of ~ $4.07 billion, the company has significant liquidity that reduces downside risk and increases optionality for capital allocation. Price-to-sales near 3.9x is reasonable for a specialized electronics/defense supplier with recurring aftermarket and service revenue.
Put differently, the stock looks expensive on trailing EPS - which has been lumpy - but more defensible on an enterprise-value-to-free-cash-flow basis when you account for the strong FCF generation and cash buffer. That dichotomy is why this trade idea is structured: we are long while keeping a tight stop to limit exposure to earnings variability or execution misses.
Catalysts that could drive the trade
- Continued order flow: A sustained cadence of large orders for nuclear instrumentation or medical detection gear would show backlog conversion and push revenue higher.
- Further margin expansion: Operating leverage as volumes recover or mix shifts to higher-margin service/aftermarket would boost earnings.
- Strategic M&A or capital return: Cash balance (~$1.49B) enables accretive tuck-ins or shareholder-friendly actions that could underpin multiple expansion.
- Sector tailwinds: Renewed government and utility spending on nuclear projects and stricter radiation safety regulations in healthcare.
- Positive macro headlines - e.g., AI data center safety projects - that have already helped in past rallies.
Trade plan (actionable)
We offer a three-horizon plan with a single entry and a single stop to keep sizing and risk management simple. Size the position so the amount at risk to the stop represents a tolerable percent of portfolio capital.
- Entry: Buy at $16.35 (limit order).
- Stop loss: $14.75 - exit if price closes below this level to protect capital and limit drawdown.
- Primary target: $19.50 - intended horizon: mid term (45 trading days). This target captures a recovery toward technical resistance near prior consolidation and a rerate if momentum resumes.
- Secondary target: $24.00 - intended horizon: long term (180 trading days). This is a stretch target if revenue conversion continues and the multiple rerates as execution proves out.
Why these levels? Entry at $16.35 keeps a tight risk band relative to the recent summer low ($14.11). The stop at $14.75 respects the low while allowing for intraday noise; breaching it would indicate the thesis is faltering. The mid-term $19.50 target is achievable if recent order trends translate into another quarter of solid revenue growth and margins inflect. The $24 target assumes both topline and margin improvement plus partial multiple expansion.
Technical backdrop
Momentum indicators have stabilized: the 10/20/50-day SMAs sit under the current price ($15.97 / $15.86 / $15.74 respectively), RSI is neutral around 54, and MACD shows bullish momentum. Short interest has been material (recent figures show north of ~35 million shares short with days-to-cover around 10-11 at one point), which can amplify both rallies and drawdowns. Be prepared for heightened intraday volatility.
Risks and counterarguments
- High headline valuation: A P/E above 160 implies investors expect steady earnings growth; any miss could trigger sharp multiple compression and downside.
- Earnings volatility: Past EPS prints have been lumpy; project-based revenue and long sales cycles mean margins and EPS can swing quarter-to-quarter.
- Investor rotation / selling: Institutional selling has occurred (notable stake reductions reported in 2026), which can pressure the stock even with good fundamentals.
- Competitive & funding risk: Defense and nuclear budgets are subject to policy and budget cycles; delays or cost overruns on large projects could push out revenue.
- Short-squeeze volatility: Elevated short interest could produce violent intraday moves on both the upside and the downside, complicating stops and execution.
Counterargument: The strongest counter is that headline earnings are modest and valuations look frothy on EPS. That is fair, but it understates the balance-sheet and cash-flow picture: free cash flow of $133.7 million and a cash hoard near $1.49 billion materially reduce bankruptcy and liquidity risk and give management options to accelerate growth or return capital. If Mirion simply executes to convert recent order growth into revenue without major margin deterioration, the multiple could re-rate even if EPS remains lumpy in the near-term.
Conclusion - stance and what would change our mind
Stance: constructive but pragmatic. We are initiating a long trade at $16.35 with a defined stop at $14.75 and a primary target of $19.50 (mid term, 45 trading days). The setup leans on durable secular demand, a strong order cadence, healthy free cash flow and a large cash balance that cushions downside.
What would change our mind: a clear deterioration in order trends or a quarterly revenue/earnings miss that erodes backlog conversion would force us to re-evaluate. Likewise, material insider selling beyond routine portfolio management, significant contract cancellations, or sudden, sustained margin deterioration would invalidate the bull case and require exiting any remaining position.
Execution checklist: buy at $16.35, size for the stop at $14.75, take partial profits into $19.50, and hold a tranche to $24.00 if fundamentals continue to improve. Keep position sizing disciplined: treat this as a medium-risk swing with a clear exit plan.
Key dates mentioned
08/02/2025 - Q2 2025 results highlighting $222.9 million revenue and raised guidance.
05/07/2026 - Insider sale reported (routine trimming by a senior officer).
07/29/2026 - 52-week low: $14.11.
10/29/2025 - Significant stock rally after a strong Q3 report.